Rapid Micro Biosystems, Inc. Class A (RPID)

Over the past six months, RPID's stock has been impacted by several events. The Q2 2025 earnings report showed revenue exceeding expectations but EPS lagging, while Q3 2025 revenue also surpassed expectations with significant recurring revenue growth. The company announced record preliminary Q4 and full-year 2025 revenue, leading to an increase in the stock price. Rapid Micro Biosystems presented at several conferences. Over the last six months, RPID stock has experienced an 8.43% decrease, with a recent fall of 18.06% in the past month, but a significant increase of 184.11% over the last year.

Rapid Micro Biosystems, Inc. experiences demand seasonality due to its customers' budgetary cycles and periods of time off, such as summer vacations and end-of-year holidays.

Rapid Micro Biosystems, Inc. (RPID) is a life sciences technology company providing automated solutions for microbial contamination detection, operating in the healthcare sector, specifically medical devices and instruments, as well as industrial machinery and life sciences tools. Its flagship product, the Growth Direct® System, is an automated microbial detection platform designed to streamline microbial quality control processes. The company also offers proprietary consumables, reagents, advanced software solutions, installation, training, validation support, and technical support services.

Rapid Micro Biosystems, Inc. has a global presence with products and services in the United States, Germany, Switzerland, Japan, and internationally. The company's headquarters are in Lexington, Massachusetts, with U.S. manufacturing facilities in Lowell, Massachusetts, and global locations in Switzerland, Germany, and the Netherlands.

Specific information detailing Rapid Micro Biosystems, Inc.'s brand reputation is not readily available. The company's messaging emphasizes the speed and reliability of its Growth Direct System. Its strategic partnership with Merck (MilliporeSigma) is seen as a positive development for market penetration and brand awareness.

Rapid Micro Biosystems, Inc. has a diverse ownership structure. Major institutional owners include Bain Capital Life Sciences Investors, LLC, ABG-WTT Global Life Science Capital Partners GP Ltd, Vanguard Group Inc, Parkman Healthcare Partners LLC, Schonfeld Strategic Advisors LLC, Advent International Corp/ma, BlackRock, Inc., BlackRock Health Sciences Trust II, Vanguard Total Stock Market Index Fund Investor Shares (VTSMX), Vanguard Extended Market Index Fund Investor Shares (VEXMX), Kennedy Lewis Management LP and Longitude Capital Management Co LLC. Approximately 30.26% to 35.20% of the company's stock is held by institutional investors, while private equity firms hold a significant 43% ownership. Insider ownership stands at 4.98%, with CEO Robert Spignesi directly holding 1.1% of the total shares outstanding. Retail investors hold a substantial portion, estimated at 59.82% or 2.36% depending on the classification of "Public Companies and Individual Investors."